Jim Cramer - Mad MoneySummit TherapeuticsSMMTDON'T BUYSep 12, 2025

The results of their cancer screening drug were poor

Move on.

Jim Cramer - Mad Money

Unlock Rating

$18.94

Stock price when the opinion was issued

$17.55

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Doesn't make money and is a risky spec.

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Capital Wealth Planning

Greg Newman

Scotia Wealth Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Jim Cramer - Mad MoneySummit TherapeuticsSMMTDON'T BUYSep 12, 2025

You might be interested:

Summit Therapeutics(SMMT)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals